[1]李萌萌,陈涛,郭在培.肿瘤坏死因子相关弱凋亡诱导因子与相关皮肤病[J].中国皮肤性病学杂志,2013,(07):85-88.
 LI Meng-meng,CHEN Tao,GUO Zai-pei.TWEAK and Related Dermatoses[J].The Chinese Journal of Dermatovenereology,2013,(07):85-88.
点击复制

肿瘤坏死因子相关弱凋亡诱导因子与相关皮肤病
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2013年07期
页码:
85-88
栏目:
出版日期:
2013-07-20

文章信息/Info

Title:
TWEAK and Related Dermatoses
作者:
李萌萌陈涛郭在培
四川大学华西医院皮肤性病科,四川 成都 610041
Author(s):
LI Meng-meng CHEN Tao GUO Zai-pei
(Department of Dermatovenereology, West China Hospital, Sichuang University, Chengdu 610041, China)
关键词:
肿瘤坏死因子相关弱凋亡诱导因子 系统性红斑狼疮 特应性皮炎 银屑病 过敏性紫癜
Keywords:
TWEAK SLE Atopic dermatitis Psoriasis Henoch-schonlein purpura
分类号:
R 751
文献标志码:
A
摘要:
肿瘤坏死因子相关弱凋亡诱导因子(tumor necrosis factor-like weak inducer of apoptosis, TWEAK)是肿瘤坏死因子超家族的成员,通过与它的受体成纤维细胞生长因子诱导14(fibroblast growth factor-inducible 14, Fn14)结合调节许多细胞活性,包括增殖、迁移、凋亡、血管生成和炎症。本文就TWEAK的分布、功能及其在皮肤科疾病中的研究进展等作一综述。
Abstract:
Tumor necrosis factor-like weak inducer of apoptosis(TWEAK), a member of the TNF superfamily, is a multifunctional cytokine. TWEAK binds to its receptor(fibroblast growth factor-inducible 14, Fn14)regulates many cellular activities, including proliferation, migration, differentiation, apoptosis, angiogenesis and inflammation. This review summarizes distribution, function of TWEAK and its study progression involved in dermatoses.

参考文献/References:

[1] Chicheportiche Y.TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis[J].J Biol Chem,1997,272(51):32401-32410.
[2] Wiley SR, Winkles JA. A member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor[J].Cytokine Growth Factor Rev,2003,14(3-4):241-249.
[3] Campbell S, Michaelson J, Burkly L, et al. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity[J].Front Biosci,2004,9(1): 2273-2284.
[4] Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis[J].Immunity,2001,15(5):837-846.
[5] Brown SA, Hanscom HN, Vu H, et al. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules[J].Biochem J, 2006,397(2):297-304.
[6] Feng SY,Guo Y,Factor VM,et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas[J].Am J Pathol,2000,156(4):1253-1261.
[7] Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator[J].J Immunol,2006,177(4):2610-2620.
[8] Meighan-Mantha RL,Hsu DK, Guo Y, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration[J].J Biol Chem,1999,274(46):33166-33176.
[9] Brown SA, Richards CM, Hanscom HN, et al. The Fn14 cytoplasmic tail binds tumour necrosis factor receptor-associated factors 1, 2, 3 and 5 and mediates NF-kappaBactivation[J].Biochem J,2003,371(Pt2):395-403.
[10] Tran NL, McDonough WS, Savitch BA, et al. The tumor necrosis factor-like weak inducer of apoptosis(TWEAK)-fibroblast growth factor-inducible 14(Fn14)signaling system regulates glioma cell survival via NF-kappaB pathway activation and BCL-XL/BCL-W expression[J].J Biol Chem,2005,280(5):3483-3492.
[11] Winkles JA, Tran NL, Brown SA, et al.Role of TWEAK and Fn14 in tumor biology[J].Front Biosei,2007,12:2761-2771.
[12] Sanz AB, Justo P, Sanchez-Nińo MD, et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation[J].J Am Soc Nephrol,2008,19(4):695-703.
[13] Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting[J].Nat Rev Drug Discov,2008,7(5):411-425.
[14] Polek TC, Talpaz M, Darnay BG, et al. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR[J].J Biol Chem,2003,278(34):32317-32323.
[15] Nalbandian A, Crispín JC, Tsokos GC.Interleukin-17 and systemic lupus erythematosus: current concepts[J].Clin Exp Immunol,2009,157(2):209-215.
[16] Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus[J].J Immunol,2007,179(11):7949-7958.
[17] Schwartz N, Rubinstein T, Burkly LC,et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study[J].Arthritis Res Ther,2009,11(5):R143.
[18] ELGendi SS, El-Sherif WT. Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement[J].Egypt J Immunol,2009,16(1):135-148.
[19] Liu ZC, Zhou OL, Li XZ, et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus[J].Cytokine,2011,53(3):295-300.
[20] Wang C, Chen LL, Pan HF,et al. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus[J].Clinical Rheumatology,2012,31(2):335-339.
[21] Trautmann A, Akdis M, Kleemann D, et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis[J].J Clin Invest,2000,106(1):25-35.
[22] Zimmermann M, Koreck A, Meyer N, et al. TNF-like weak inducer of apoptosis(TWEAK)and TNF-α cooperate in the induction of keratinocyte apoptosis[J].J Allergy Clin Immunol,2011,127(1):200-207.
[23] van Kuijk AW, Wijbrandts CA, Vinkenoog M, et al. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade[J].Ann Rheum Dis,2010,69(1):301-304.
[24] Xia L, Shen H, Xiao W, et al. Increased serum TWEAK levels in psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels[J].Cytokine,2011,53(3):289-291.
[25] Tarshish P, Bernstein J, Edelmann CM. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide[J].Pediatr Nephrol,2004,19(1):51-56.
[26] Chen T, Guo ZP, Li MM, et al. Tumour necrosis factor-like weak inducer of apoptosis(TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura[J].Clin Exp Immunol,2011,166(1):64-71.
[27] Mulligan-Kehoe MJ, Simons M. Vascular disease in scleroderma: angiogenesis and vascular repair[J].Rheum Dis Clin North Am,2008,34(1):73-79.
[28] Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis[J].Rheumatology(Oxford),2009,48(Suppl 3):iii3-7.
[29] Distler JH, Akhmetshina A, Schett G,et al.Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis[J].Rheumatology(Oxford),2009,48(2):98-103.
[30] Yanaba K, Yoshizaki A, Muroi E,et al. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis[J].J Rheumatol,2009,36(8):1657-1662.
[31] Bielecki M, Kowal K, Lapinska A, et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis[J].Folia Histochem Cytobiol,2009,47(3):465-469.
[32]Abend JR, Uldrick T, Ziegelbauer JM. Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein(TWEAKR)expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and infiammatory cytokine expression[J].Journal of virology,2010,84(23):12139-12151.
[33] Kang S, Yang C, Luo R. Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells[J].Biochem Biophys Res Commun,2008,372(4):629-633.
[34] Peternel S, Manestar-Blazic T, Brajac I, et al. Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes[J].J Cutan Pathol,2011,38(10):780-789.

相似文献/References:

[1]杨露露,崔勇,杨森.几种合成肽对系统性红斑狼疮治疗作用的研究进展[J].中国皮肤性病学杂志,2016,(12):1284.[doi:10.13735/j.cjdv.1001-7089.201503083]
 YANG Lu-lu,CUI Yong,YANG Sen.The Progress in the Treatment of Systemic Lupus Erythematosus with Synthetic Peptides[J].The Chinese Journal of Dermatovenereology,2016,(07):1284.[doi:10.13735/j.cjdv.1001-7089.201503083]
[2]周莹.系统性红斑狼疮并发股骨头坏死研究进展[J].中国皮肤性病学杂志,2017,(08):918.[doi:10.13735/j.cjdv.1001-7089.201606062]
 ZHOU Ying.Osteonecrosis of the Femoral Head in Patients with Systemic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2017,(07):918.[doi:10.13735/j.cjdv.1001-7089.201606062]
[3]伊力努尔·哈力甫,梁俊琴,胡凤侠,等.免疫球蛋白受体ⅡB和ⅢA基因多态性与新疆维吾尔族SLE的遗传易感性分析[J].中国皮肤性病学杂志,2018,(12):1355.[doi:10.13735/j.cjdv.1001-7089.201804128]
 Yilinuer Halifu,LIANG Junqin,HU Fengxia,et al.Association of Polymorphisms in Immunoglobulin Receptor ⅡB and ⅢA Genes with Hereditary Susceptibility of Systemic Lupus Erythematosus in Xinjiang[J].The Chinese Journal of Dermatovenereology,2018,(07):1355.[doi:10.13735/j.cjdv.1001-7089.201804128]
[4]范思奇,曾平,秦刚,等.系统性红斑狼疮并发股骨头坏死危险因素的Meta分析[J].中国皮肤性病学杂志,2018,(12):1451.[doi:10.13735/j.cjdv.1001-7089.201801016]
 FAN Siqi,ZENG Ping,QIN Gang,et al.Meta-analysis of Risk Factors for Aseptic Femoral Head Necrosis in Patients with Systemic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2018,(07):1451.[doi:10.13735/j.cjdv.1001-7089.201801016]
[5]熊梦燎,李卉,周文明.皮肌炎和系统性红斑狼疮重叠综合征伴Degos样皮疹1例[J].中国皮肤性病学杂志,2020,(08):915.[doi:10.13735/j.cjdv.1001-7089.201909066]
 XIONG Mengliao,LI Hui,ZHOU Wenming.A Case of Degos-like Lesions in Systemic Lupus Erythematosus-Dermatomyositis Overlap Syndrome[J].The Chinese Journal of Dermatovenereology,2020,(07):915.[doi:10.13735/j.cjdv.1001-7089.201909066]

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金(81101198) [作者单位] 四川大学华西医院皮肤性病科,四川 成都 610041 [通讯作者] 郭在培,E-mail:guozp930@163.com
更新日期/Last Update: 2013-07-20